Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2024.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Ellen Hein Nordvig und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. Electronic address: ellen.hein.frederiksen@regionh.dk. Hauptthemen laut MEDLINE: Rectal Neoplasms, Induction Chemotherapy, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Total neoadjuvant treatment (TNT) with induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) has improved long-term outcomes for patients with locally advanced rectal cancer (LARC). However, long-term outcomes have not been investigated for patients with incomplete (R1) resection separately. This study investigates overall survival (OS), disease-free survival (DFS) and local and distant recurrence rates in patients with R1 resection after preoperative treatment with ICT and CRT or CRT. PATIENTS AND METHODS: From the NORD database 689 patients with LARC who received treatment between 2006 and 2017 were screened for inclusion. All patients with R1 resection were included. ICT consisted of at least 1 cycle of capecitabine and oxaliplatin (CAPOX) and was followed by radiotherapy concomitant with capecitabine. RESULTS: Among 46 patients with R1 resection, 27 (59%) received both ICT and CRT, and 19 (41%) patients received CRT. The 5-year OS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 37% (95% CI, 15%-59%) (CRT) (P = .25) and 5-year DFS was 44% (95% CI, 26%-63%) (ICT + CRT) versus 32% (95% CI, 11%-53%) (CRT) (P = .22). The local recurrence rates showed a small nonstatistical significant difference in local control in the ICT group: 15% compared to 26% in the CRT group (P = .22). Distant recurrence rates were similar: 41% (ICT + CRT) versus 47% (CRT) (P = .48). CONCLUSION: There was no significant difference in OS, DFS or local and distant recurrence rates between patients who received ICT + CRT versus patients who received CRT only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. Electronic address: ellen.hein.frederiksen@regionh.dk.
- Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark.
- Department of Gastrointestinal Surgery, Herlev and Gentofte Hospital, Herlev, Denmark.
Zitieren
APA
Hein Nordvig, E., Bergliot Grønbæk, G. M., Khalid Al-Uboody, Z., Lykke, J., Hagen Vasehus Schou, J., & Østergaard Poulsen, L. (2025). Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.09.003
Vancouver
Hein Nordvig E, Bergliot Grønbæk GM, Khalid Al-Uboody Z, Lykke J, Hagen Vasehus Schou J, Østergaard Poulsen L. Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.09.003
BibTeX
@article{HeinNordvig2025,
author = {Hein Nordvig, Ellen and Bergliot Grønbæk, Gull-Mai and Khalid Al-Uboody, Zahra and Lykke, Jakob and Hagen Vasehus Schou, Jakob and Østergaard Poulsen, Laurids},
title = {Long-Term Outcomes in Patients With Locally Advanced Rectal Cancer Following R1 Resection After Either Induction Chemotherapy and Chemoradiotherapy or Chemoradiotherapy Alone},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2024.09.003}
}
EUVIMED